Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for primary percutaneous coronary revascularisation of acute myocardial infarction
EuroIntervention 2016;12:e1343-e1354 published online ahead of print December 2015 published online e-edition December 2016. DOI: 10.4244/EIJY15M12_09
Thomas Pilgrim1*, MD; Raffaele Piccolo1, MD; Dik Heg2, PhD; Marco Roffi3, MD; David Tüller4, MD; André Vuilliomenet5, MD; Olivier Muller6, MD; Stéphane Cook7, MD; Daniel Weilenmann8, MD; Christoph Kaiser9, MD; Peiman Jamshidi10, MD; Ahmed A. Khattab1, MD; Masanori Taniwaki1, MD; Fabio Rigamonti3, MD; Fabian Nietlispach1, MD; Stefan Blöchlinger1, MD; Peter Wenaweser1, MD; Peter Jüni11,12, MD; Stephan Windecker1, MD
1. Department of Cardiology, Swiss Cardiovascular Center, University Hospital, Bern, Switzerland; 2. Institute of Social and Preventive Medicine and Clinical Trials Unit, Bern University Hospital, Bern, Switzerland; 3. Department of Cardiology, University
Aims: Our aim was to compare the safety and efficacy of a novel, ultrathin strut, biodegradable polymer sirolimus-eluting stent (BP-SES) with a thin strut, durable polymer everolimus-elut
